New prolonged-release metformin improves gastrointestinal tolerability
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Current guidelines for the management of type 2 diabetes recommend initiating pharmacological therapy with metformin, particularly in overweight patients, but gastrointestinal side-effects and a complex administration regimen sometimes present barriers to its use. A novel, prolonged-release metformin formulation (Glucophage® SR*), given once-daily in double-blind, randomised, placebo-controlled trials, was associated with fewer gastrointestinal side-effects, than immediate-release metformin. A retrospective review of 468 metformin-treated patients in the USA found better gastrointestinal tolerability with prolonged-release metformin in patients new to metformin, or switched from the immediate-release formulation. The efficacy of the two formulations was similar. The improved tolerability associated with prolonged-release metformin probably arises from the tablet design, which releases metformin into the upper intestine by diffusion from a dual hydrophilic polymer matrix (GelShield diffusion system). This provides slower, smoother and longer drug delivery, without an initial rapid rise in plasma metformin. This novel metformin formulation may simplify the delivery of metformin-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Fujioka, K., Brazg, R. L., Raz, I., Bruce, S., Joyal, S., Swanink, R., & Pans, M. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00369.x · Cited by 73
Cited by
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
“Gastrointestinal intolerance occurs with both the immediate and sustained-releasemetformin but, on average, the sustainedrelease formulation is better tolerated.([24,25]) As a result, patients often show improved gastrointestinal tolerance of metformin if changed from immediate-release to sustained-release metformin a…”
BackgroundMetformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733
“On contact with fluid from the GI tract, the tablet swells, and the metformin is released as the polymer gradually breaks down [14].”
BackgroundMetformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
Self-citationUnderstanding and overcoming metformin gastrointestinal intolerance
Bonnet, F., & Scheen, A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12854 · Cited by 256
Metadata
- Authors
- Davidson, J., & Howlett, H.
- Venue
- The British Journal of Diabetes & Vascular Disease
- Publisher
- SAGE Publications
- Published
- 2004-07
- Volume
- 4
- Issue
- 4
- Pages
- 273-277
- ISSN
- 1474-6514 (ISSN-L)
- 1753-4305
- OpenAlex
- W2116270854
- Cited by
- 38
- References
- 2
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New prolonged-release metformin improves gastrointestinal tolerability. https://app.cochat.ai/papers/10.1177/14746514040040041101
- The paper
- Davidson, J., & Howlett, H. (2004). New prolonged-release metformin improves gastrointestinal tolerability. The British Journal of Diabetes & Vascular Disease. https://doi.org/10.1177/14746514040040041101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.